ArticleScientific reports2026
Formulation of bacterial cellulose nanofibrils incorporated with xanthone as functional green ingredients for cosmeceutical products.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering pectin- and sodium alginate-based nanoemulgels for topical delivery ofRSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study developed a bio-based gel using bacterial cellulose nanofibrils (BCNF) as a natural moisturizing and delivery matrix, and xanthone, an active ingredient from Garcinia mangostana peel, with known antimicrobial, anti-inflammatory, and antioxidant properties. BCNF was produced through a mechanical defibrillation process, resulting in nanofibers with an average diameter of 32.12 ± 2.54 nm. FTIR and WAXS analyses confirmed successful Xanthone incorporation into the BCNF matrix. The composite demonstrated moderate anti-inflammatory activity, inhibiting albumin denaturation with an IC50 value of 33.00 ± 2.72 mg/mL and nitric oxide inhibition of 28.66 ± 3.75% similar to triamcinolone acetonide, at the concentration of 1 mg/mL. Antibacterial assays revealed effective inhibition of Cutibacterium acnes and Staphylococcus aureus, with MIC values of 0.976 and 3.906 mg/mL, respectively. The acne gel formulated with BCNF/Xanthone showed stable antioxidant activity over 30 days, as evaluated by DPPH assay. Overall, the formulation 4 (F4), which used BCNF/Xanthone as the sole stabilizer and bioactive carrier showed the highest free radical scavenging activity and killing efficiency against S. aureus. Rheological assessments confirmed that BCNF/Xanthone enhanced gel viscosity and resulted in non-Newtonian, shear-thinning flow behavior, and stable pH value after 30 days, suitable for topical application. These findings suggest that BCNF/Xanthone offer a sustainable, effective alternative with multifunctional benefits for acne management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.